Cargando…
LGG-08. MR Imaging of pediatric low-grade gliomas: Pretherapeutic differentiation ofBRAF V600E mutation,BRAF-Fused and Wild-Type tumors in patients without Neurofibromatosis-1
OBJECTIVE: The prognosis and treatment of pediatric low-grade gliomas (pLGGs) is influenced by their molecular subtype. MRI remains the mainstay for initial work-up and surgical planning. We aimed to determine the relationship between imaging patterns and molecular subtypes of pLGGs. METHODS: This i...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165166/ http://dx.doi.org/10.1093/neuonc/noac079.324 |
_version_ | 1784720325551849472 |
---|---|
author | Trasolini, Andrew Erker, Craig Cheng, Sylvia Crowell, Cameron McFadden, Kathryn Moineddin, Rahim Sargent, Michael Mata-Mbemba, Daddy |
author_facet | Trasolini, Andrew Erker, Craig Cheng, Sylvia Crowell, Cameron McFadden, Kathryn Moineddin, Rahim Sargent, Michael Mata-Mbemba, Daddy |
author_sort | Trasolini, Andrew |
collection | PubMed |
description | OBJECTIVE: The prognosis and treatment of pediatric low-grade gliomas (pLGGs) is influenced by their molecular subtype. MRI remains the mainstay for initial work-up and surgical planning. We aimed to determine the relationship between imaging patterns and molecular subtypes of pLGGs. METHODS: This is a bi-institutional retrospective study for patients diagnosed from 2004 to 2021 with pathologically confirmed pLGG, molecularly defined as BRAF fusion (KIAA1549-BRAF), BRAF V600E mutation, or wild-type (negative for both BRAF V600E mutation and BRAF fusion). Two neuroradiologists, blinded, independently reviewed imaging parameters on the initial MRI and discrepancies were solved by consensus. Bivariate analysis was used followed by pairwise comparison of Dwass, Steel, and Critchlow-Fligner methods to compare the 3 molecular subtypes. Agreement between reviewers was assessed using Kappa (k). RESULTS: 70 patients were included: 30 with BRAF fusion, 19 with BRAF V600E mutation, and 21 wild-type. There was substantial agreement between the two readers for overall imaging variables (k=0.75). BRAF fusion tumors compared to V600E and wild-type had larger size (p=0.0022), greater mass effect (p=0.0053), and increased rate of hydrocephalus (p=0.0002). BRAF fusion tumors had increased frequency of diffuse enhancement compared with BRAF V600E and wild-type (p <0.0001). BRAF V600E mutant tumors were more often located in a cerebral hemisphere (p <0.0001). Diffusion restriction (qualitatively) was uncommon but only seen in BRAF V600E (p=0.0042) with lower ADC ratio (quantitatively) (p=0.003). Additionally, BRAF V600E mutant tumors appeared more infiltrative than BRAF fusion and wild-type (p=0.0002). CONCLUSION:BRAF fusion and BRAF V600E mutant pLGG have unique imaging features that can be used to differentiate from each other and wild-type pLGG using standard radiology review with high inter-reader agreement. In the era of targeted therapy, these features can be useful for therapeutic planning prior to surgery. |
format | Online Article Text |
id | pubmed-9165166 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-91651662022-06-05 LGG-08. MR Imaging of pediatric low-grade gliomas: Pretherapeutic differentiation ofBRAF V600E mutation,BRAF-Fused and Wild-Type tumors in patients without Neurofibromatosis-1 Trasolini, Andrew Erker, Craig Cheng, Sylvia Crowell, Cameron McFadden, Kathryn Moineddin, Rahim Sargent, Michael Mata-Mbemba, Daddy Neuro Oncol Low Grade Glioma OBJECTIVE: The prognosis and treatment of pediatric low-grade gliomas (pLGGs) is influenced by their molecular subtype. MRI remains the mainstay for initial work-up and surgical planning. We aimed to determine the relationship between imaging patterns and molecular subtypes of pLGGs. METHODS: This is a bi-institutional retrospective study for patients diagnosed from 2004 to 2021 with pathologically confirmed pLGG, molecularly defined as BRAF fusion (KIAA1549-BRAF), BRAF V600E mutation, or wild-type (negative for both BRAF V600E mutation and BRAF fusion). Two neuroradiologists, blinded, independently reviewed imaging parameters on the initial MRI and discrepancies were solved by consensus. Bivariate analysis was used followed by pairwise comparison of Dwass, Steel, and Critchlow-Fligner methods to compare the 3 molecular subtypes. Agreement between reviewers was assessed using Kappa (k). RESULTS: 70 patients were included: 30 with BRAF fusion, 19 with BRAF V600E mutation, and 21 wild-type. There was substantial agreement between the two readers for overall imaging variables (k=0.75). BRAF fusion tumors compared to V600E and wild-type had larger size (p=0.0022), greater mass effect (p=0.0053), and increased rate of hydrocephalus (p=0.0002). BRAF fusion tumors had increased frequency of diffuse enhancement compared with BRAF V600E and wild-type (p <0.0001). BRAF V600E mutant tumors were more often located in a cerebral hemisphere (p <0.0001). Diffusion restriction (qualitatively) was uncommon but only seen in BRAF V600E (p=0.0042) with lower ADC ratio (quantitatively) (p=0.003). Additionally, BRAF V600E mutant tumors appeared more infiltrative than BRAF fusion and wild-type (p=0.0002). CONCLUSION:BRAF fusion and BRAF V600E mutant pLGG have unique imaging features that can be used to differentiate from each other and wild-type pLGG using standard radiology review with high inter-reader agreement. In the era of targeted therapy, these features can be useful for therapeutic planning prior to surgery. Oxford University Press 2022-06-03 /pmc/articles/PMC9165166/ http://dx.doi.org/10.1093/neuonc/noac079.324 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Low Grade Glioma Trasolini, Andrew Erker, Craig Cheng, Sylvia Crowell, Cameron McFadden, Kathryn Moineddin, Rahim Sargent, Michael Mata-Mbemba, Daddy LGG-08. MR Imaging of pediatric low-grade gliomas: Pretherapeutic differentiation ofBRAF V600E mutation,BRAF-Fused and Wild-Type tumors in patients without Neurofibromatosis-1 |
title | LGG-08. MR Imaging of pediatric low-grade gliomas: Pretherapeutic differentiation ofBRAF V600E mutation,BRAF-Fused and Wild-Type tumors in patients without Neurofibromatosis-1 |
title_full | LGG-08. MR Imaging of pediatric low-grade gliomas: Pretherapeutic differentiation ofBRAF V600E mutation,BRAF-Fused and Wild-Type tumors in patients without Neurofibromatosis-1 |
title_fullStr | LGG-08. MR Imaging of pediatric low-grade gliomas: Pretherapeutic differentiation ofBRAF V600E mutation,BRAF-Fused and Wild-Type tumors in patients without Neurofibromatosis-1 |
title_full_unstemmed | LGG-08. MR Imaging of pediatric low-grade gliomas: Pretherapeutic differentiation ofBRAF V600E mutation,BRAF-Fused and Wild-Type tumors in patients without Neurofibromatosis-1 |
title_short | LGG-08. MR Imaging of pediatric low-grade gliomas: Pretherapeutic differentiation ofBRAF V600E mutation,BRAF-Fused and Wild-Type tumors in patients without Neurofibromatosis-1 |
title_sort | lgg-08. mr imaging of pediatric low-grade gliomas: pretherapeutic differentiation ofbraf v600e mutation,braf-fused and wild-type tumors in patients without neurofibromatosis-1 |
topic | Low Grade Glioma |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165166/ http://dx.doi.org/10.1093/neuonc/noac079.324 |
work_keys_str_mv | AT trasoliniandrew lgg08mrimagingofpediatriclowgradegliomaspretherapeuticdifferentiationofbrafv600emutationbraffusedandwildtypetumorsinpatientswithoutneurofibromatosis1 AT erkercraig lgg08mrimagingofpediatriclowgradegliomaspretherapeuticdifferentiationofbrafv600emutationbraffusedandwildtypetumorsinpatientswithoutneurofibromatosis1 AT chengsylvia lgg08mrimagingofpediatriclowgradegliomaspretherapeuticdifferentiationofbrafv600emutationbraffusedandwildtypetumorsinpatientswithoutneurofibromatosis1 AT crowellcameron lgg08mrimagingofpediatriclowgradegliomaspretherapeuticdifferentiationofbrafv600emutationbraffusedandwildtypetumorsinpatientswithoutneurofibromatosis1 AT mcfaddenkathryn lgg08mrimagingofpediatriclowgradegliomaspretherapeuticdifferentiationofbrafv600emutationbraffusedandwildtypetumorsinpatientswithoutneurofibromatosis1 AT moineddinrahim lgg08mrimagingofpediatriclowgradegliomaspretherapeuticdifferentiationofbrafv600emutationbraffusedandwildtypetumorsinpatientswithoutneurofibromatosis1 AT sargentmichael lgg08mrimagingofpediatriclowgradegliomaspretherapeuticdifferentiationofbrafv600emutationbraffusedandwildtypetumorsinpatientswithoutneurofibromatosis1 AT matambembadaddy lgg08mrimagingofpediatriclowgradegliomaspretherapeuticdifferentiationofbrafv600emutationbraffusedandwildtypetumorsinpatientswithoutneurofibromatosis1 |